These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34463936)

  • 1. Surface Ligand Valency and Immunoliposome Binding: when More Is Not Always Better.
    Li H; Di J; Peng B; Xu Y; Zhang N
    Pharm Res; 2021 Sep; 38(9):1593-1600. PubMed ID: 34463936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes).
    Jin S; Li H; Xu Y
    Methods Mol Biol; 2023; 2622():197-205. PubMed ID: 36781762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.
    Biswas S; Dodwadkar NS; Sawant RR; Torchilin VP
    Bioconjug Chem; 2011 Oct; 22(10):2005-13. PubMed ID: 21870873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique.
    Bendas G; Krause A; Bakowsky U; Vogel J; Rothe U
    Int J Pharm; 1999 Apr; 181(1):79-93. PubMed ID: 10370205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.
    Maruyama K; Takizawa T; Yuda T; Kennel SJ; Huang L; Iwatsuru M
    Biochim Biophys Acta; 1995 Mar; 1234(1):74-80. PubMed ID: 7880861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the activity of maleimide-functionalized phospholipids during preparation of liposomes.
    Oswald M; Geissler S; Goepferich A
    Int J Pharm; 2016 Nov; 514(1):93-102. PubMed ID: 27863688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
    Wang D; Sun Y; Liu Y; Meng F; Lee RJ
    Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of Immunoliposomes by Direct Coupling of Antibodies Based on a Thioether Bond.
    Petrilli R; Eloy JO; Lee RJ; Lopez RFV
    Methods Mol Biol; 2018; 1674():229-237. PubMed ID: 28921442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.
    Torchilin VP; Levchenko TS; Lukyanov AN; Khaw BA; Klibanov AL; Rammohan R; Samokhin GP; Whiteman KR
    Biochim Biophys Acta; 2001 Apr; 1511(2):397-411. PubMed ID: 11286983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEG-immunoliposome.
    Maruyama K
    Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of ligand valency and density on the targeting ability of multivalent nanoparticles based on negatively charged chitosan nanoparticles.
    Cao J; Zhang Y; Wu Y; Wu J; Wang W; Wu Q; Yuan Z
    Colloids Surf B Biointerfaces; 2018 Jan; 161():508-518. PubMed ID: 29128837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.
    Jiang S; Wang X; Zhang Z; Sun L; Pu Y; Yao H; Li J; Liu Y; Zhang Y; Zhang W
    Int J Nanomedicine; 2016; 11():5505-5518. PubMed ID: 27843311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
    Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
    Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-ligand α
    Levine RM; Kokkoli E
    J Control Release; 2017 Apr; 251():24-36. PubMed ID: 28215671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future directions of liposome- and immunoliposome-based cancer therapeutics.
    Park JW; Benz CC; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes.
    Li WM; Xue L; Mayer LD; Bally MB
    Biochim Biophys Acta; 2001 Aug; 1513(2):193-206. PubMed ID: 11470091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
    Klibanov AL; Maruyama K; Beckerleg AM; Torchilin VP; Huang L
    Biochim Biophys Acta; 1991 Feb; 1062(2):142-8. PubMed ID: 2004104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.